| Autor: |
Kenji Katsumata, Tetsuo Sumi, Tatehiko Wada, Yasuharu Mori, Masayuki Hisada, Hideaki Kawakita, Masanori Enomoto, Shoji Suzuki, Daisuke Matsuda, Akihiko Tsuchida, Tatsuya Aoki |
| Jazyk: |
angličtina |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
Clinical Medicine Insights: Oncology, Vol 2 (2008) |
| Druh dokumentu: |
article |
| ISSN: |
1179-5549 |
| DOI: |
10.4137/CMO.S412 |
| Popis: |
Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m 2 ) and l-leucovorin(l-LV) (200 mg/m 2 ), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m 2 ) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m 2 ) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
